The Annual General Meeting of Targovax ASA (the “Company”) will be held at the Company’s offices at Lysaker, on 30 April 2019 at 13:00 CET.
Please find the notice including agenda for the General Meeting and appendices attached to this disclosure. The notice and appendices will also be made available on Targovax’ website https://www.targovax.com/en/section/governance/general-meetings/.
Notice of attendance must be received no later than 29 April 2019 at 16:00 CET.
Reference is also made to the Company’s stock exchange announcement on 27 March 2019 regarding the terms and conditions for the proposed subsequent offering in the Company. The Company’s board of directors has proposed to re-schedule the subscription period in the subsequent offering, since the Company expects to read out 3-year survival data for TG01 during this new subscription period. The re-scheduled subscription period will commence at 09:00 hours (CEST) on 10 May 2019 and expire at 16:30 hours (CEST) on 24 May 2019.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Media and IR enquires:
Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.
Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.